Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,123.78
    +44.92 (+0.56%)
     

  • Bitcoin USD

    63,910.61
    +748.56 (+1.19%)
     

  • CMC Crypto 200

    1,378.62
    -17.92 (-1.28%)
     

  • S&P 500

    5,084.72
    +36.30 (+0.72%)
     

  • Dow

    38,149.50
    +63.70 (+0.17%)
     

  • Nasdaq

    15,830.44
    +218.68 (+1.40%)
     

  • Gold

    2,354.70
    +12.20 (+0.52%)
     

  • Crude Oil

    84.34
    +0.77 (+0.92%)
     

  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Why MyoKardia Shares Rose 62.8% in May

Adria Cimino, The Motley Fool
·2-min read
Why MyoKardia Shares Rose 62.8% in May

Shares of MyoKardia (NASDAQ: MYOK) climbed 62.8% in May, according to data provided by S&P Global Market Intelligence, after the company said its investigational heart drug met primary and secondary endpoints in a phase 3 clinical trial. Mavacamten is a treatment for obstructive hypertrophic cardiomyopathy (HCM), a chronic and progressive disease of the heart that results in reduced pumping capacity. In the phase 3 trial, the primary endpoint was a functional analysis that measured the drug's performance relative to placebo on symptoms and cardiac function.

Continue reading